Rosen Law Firm Urges Bolt Biotherapeutics Investors to Act Before Deadline in Class Action Lawsuit

NEW YORK, Aug. 17, 2024 (GLOBE NEWSWIRE) -- The Rosen Law Firm, a prestigious global investor rights law firm, has issued a call to action for all investors who purchased securities from Bolt Biotherapeutics, Inc. BOLT during the period of February 5, 2021, and May 14, 2024. The firm underscores the urgency for the affected shareholders to seek legal counsel ahead of the rapidly approaching deadline of September 3, 2024, which marks the end of the lead plaintiff motion period in the ongoing securities class action lawsuit against the company.

Understanding the Case Against BOLT

Bolt Biotherapeutics, Inc., operating within the promising sector of immuno-oncology, is facing legal scrutiny as allegations of potential securities violations surface, questioning the company's business practices and disclosures during the specified 'Class Period.' The lawsuit targets the management's responsibilities and the potential harm to investors stemming from the alleged misconduct. The claim seeks to address the losses incurred by those who invested in BOLT shares during the period in question, and who may have been affected by the actions of the company's executives.

About Bolt Biotherapeutics, Inc.

Headquartered in Redwood City, California, Bolt Biotherapeutics BOLT is at the forefront of immuno-oncology research. The company focuses on the development and commercialization of innovative pharmaceutical products that harness the body's immune system to fight cancer. Their commitment to advancing clinical-stage treatments positions them as a prominent player in the biotechnology industry.

Action Steps for Investors

This announcement serves as a critical reminder to BOLT shareholders that there is a limited time to petition the court for a role as a lead plaintiff. Investors are encouraged to contact qualified legal representation to assist them in potentially recouping financial losses and ensuring their interests are adequately represented in the proceedings. While this does not require the sale of any shares, it remains a pivotal legal step in the class action lawsuit, which seeks reparations for investors potentially misled by the company's alleged violations.

Investment, Legal, Deadline